efzofitimod

Phase 3Small molecule

AaTyr Pharma, Inc.

efzofitimod is one of 36 small molecule programs targeting Pulmonary Sarcoidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

Interstitial Lung DiseaseRecruiting

Pulmonary SarcoidosisPhase 3

Active, not recruiting

Interstitial Lung DiseasePhase 2

Recruiting

Competition

Competitive Landscape

38 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

5 2

Tracleer

Johnson & Johnson

Approved

3 3

Medrol

Pfizer

Approved

2 4

Trexall

Jazz Pharmaceuticals

Approved

2 5

Esbriet

LLegacy Health System

Approved

5 6

Cytoxan

BBaxter Healthcare Corporation

Approved

3 7

Actemra

CCelltrion

Approved

2 8

Cellcept

Roche

Phase 3

4 9

Imuran

LLegacy Health System

Ofev

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Recruiting·AaTyr Pharma, Inc.·Phase 2·NCT05892614·25 enrolled

Pulmonary Sarcoidosis1 trial

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Active, not recruiting·AaTyr Pharma, Inc.·Phase 3·NCT05415137·268 enrolled

Pneumonia1 trial

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Completed·AaTyr Pharma, Inc.·Phase 2·NCT04412668·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for efzofitimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — efzofitimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for efzofitimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — aTyr Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AaTyr Pharma, Inc.

efzofitimod

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interstitial Lung Disease1 trial

Pulmonary Sarcoidosis1 trial

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News